Acepro Tablet 100 mg

Acepro Tablet, manufactured by The White Horse Pharmaceuticals Ltd, contains Aceclofenac 100 mg as its active ingredient. This non-steroidal anti-inflammatory drug (NSAID) is prescribed for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, dental pain, and injury-related inflammation. Priced at ৳4.50 per unit (50’s pack: ৳225.00), it offers an affordable solution for chronic pain management.

The extended-release tablet is taken once daily (200 mg), while the film-coated variant requires twice-daily dosing (100 mg). As a cyclooxygenase (COX) enzyme inhibitor, Acepro reduces prostaglandin synthesis, alleviating pain and swelling. Users should store it in a dry, cool place and avoid combining it with diuretics or anticoagulants to prevent interactions.

Common side effects include mild indigestion, nausea, or skin rashes. Although generally safe, consult a doctor if pregnant or breastfeeding. Explore more tablet-based NSAIDs for alternative options. Acepro’s efficacy and competitive pricing make it a preferred choice in Bangladesh’s pharmaceutical market.

Extended-release tablet: 200 mg once daily. Film-coated tablet: 100 mg twice daily. Dose reduction needed in renal/hepatic impairment. Take with food and water. Avoid prolonged use beyond 10 days without medical supervision.

Acepro is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.

Pregnancy category D. Avoid in third trimester. Use during lactation contraindicated due to secretion in breast milk. Consider risk-benefit ratio in first/second trimester.

Use lowest effective dose in elderly >60 years. Monitor renal/liver function during prolonged therapy. Avoid driving due to dizziness risk. Discontinue immediately if black stools appear.

Pediatric safety not established. Geriatric patients require renal monitoring. Hepatic impairment needs 50% dose reduction. Avoid in severe renal failure (CrCl <30 mL/min).